Literature DB >> 12845184

Predictors of adverse long-term outcome in acute myocardial infarction patients undergoing primary percutaneous transluminal coronary angioplasty: with special reference to the admission concentration of lipoprotein (a).

Yutaka Igarashi1, Yoshiyasu Aizawa, Tadashi Satoh, Taku Konno, Kenji Ojima, Yoshifusa Aizawa.   

Abstract

The predictive values for long-term outcome in 127 consecutive patients with acute myocardial infarction (AMI) after successful primary percutaneous transluminal coronary angioplasty (PTCA) were prospectively investigated in the present study. The primary endpoint was a composite of cardiac death, nonfatal AMI, and recurrent angina. Follow-up angiography was performed in 120 patients to assess restenosis. The primary endpoint occurred in 21 patients during a follow-up period of 35+/-24 months. These patients had a higher lipoprotein(a) [Lp(a)] concentration (p=0.0105) and more prevalence of multivessel disease (p=0.0028) than the other patients. The subjects were divided into 2 groups at the 75th percentile Lp(a) value: group A had an Lp(a) concentration >or=47 mg/dl and group B <47 mg/dl. Kaplan-Meier analysis showed a lower cardiac event-free survival rate in group A (p=0.0007) and in patients with multivessel disease (p=0.001). In Cox proportional hazards regression analysis, an Lp(a) level >or=47 mg/dl (relative risk[RR] 5.5, 95% confidence interval [CI] 2.0-15.0, p=0.0007) and multivessel disease (RR 5.3, 95% CI 2.0-13.7, p=0.0006) were independent predictors of the primary endpoint. An elevated Lp(a) concentration on admission and multivessel disease are significant predictors for long-term adverse outcome in AMI patients treated by primary PTCA.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12845184     DOI: 10.1253/circj.67.605

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  4 in total

Review 1.  South Asian Cardiovascular Disease & Cancer Risk: Genetics & Pathophysiology.

Authors:  Latha Palaniappan; Arun Garg; Enas Enas; Henrietta Lewis; Sehrish Bari; Martha Gulati; Cristina Flores; Ashish Mathur; Cesar Molina; Jagat Narula; Shahid Rahman; Jennifer Leng; Francesca Gany
Journal:  J Community Health       Date:  2018-12

Review 2.  Lipoprotein(a): An independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction.

Authors:  Enas A Enas; Basil Varkey; T S Dharmarajan; Guillaume Pare; Vinay K Bahl
Journal:  Indian Heart J       Date:  2019-03-20

3.  Predicting Cardiovascular Outcomes by Baseline Lipoprotein(a) Concentrations: A Large Cohort and Long-Term Follow-up Study on Real-World Patients Receiving Percutaneous Coronary Intervention.

Authors:  Hui-Hui Liu; Ye-Xuan Cao; Jing-Lu Jin; Hui-Wen Zhang; Qi Hua; Yan-Fang Li; Yuan-Lin Guo; Cheng-Gang Zhu; Na-Qiong Wu; Rui-Xia Xu; Xie-Hui Chen; Jian-Jun Li
Journal:  J Am Heart Assoc       Date:  2020-01-30       Impact factor: 5.501

Review 4.  Lipoprotein(a) in cardiovascular diseases.

Authors:  Michele Malaguarnera; Marco Vacante; Cristina Russo; Giulia Malaguarnera; Tijana Antic; Lucia Malaguarnera; Rita Bella; Giovanni Pennisi; Fabio Galvano; Alessandro Frigiola
Journal:  Biomed Res Int       Date:  2012-12-30       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.